micro News and Research

RSS

Is the Pfizer-BioNTech COVID vaccine still effective after 6 months?

A team of researchers assessed the effectiveness of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine.

21 Sep 2021

New cell-free antibody generation platform successfully creates neutralizing antibodies effective against SARS-CoV-2

Researchers from the Broad Institute of MIT and Harvard have created a cell-free nanobody engineering platform that can produce antibodies effectively and quickly.

21 Sep 2021

Changes in fibrin clot structure contributes to thrombosis risk in severe COVID-19

Researchers from Europe recently demonstrated altered levels of factor XII (FXII) and its activation products in 2 independent cohorts of critically ill patients with COVID-19 compared to patients suffering from severe acute respiratory distress syndrome caused by the influenza virus (acute respiratory distress syndrome (ARDS)-influenza).

21 Sep 2021

A novel FACS-based approach for SARS-CoV-2 serology

A recent study discusses a simple, sensitive, and quantitative serological test based on FACS assay to evaluate antibodies against SARS-CoV-2.

20 Sep 2021

Large scale 'proteogenomics' study could offer hope to patients with deadly pancreatic cancer

A large international collaboration led by researchers from the Johns Hopkins Kimmel Cancer Center has identified promising new targets for pancreatic cancer treatment and early diagnosis after examining various aspects of these tumors' genes and proteins.

20 Sep 2021

Hypertension in COVID-19-affected pregnancy linked to high SARS-CoV-2 load in placenta

A new study finds that hypertension following the viral infection is associated with high placental viral load in pregnant women with COVID-19.

20 Sep 2021

Antiviral compound RG10 acts via intracellular SARS-CoV-2-ER dynamics

A new study describes a small molecule referred to as RG10 that may have potent antiviral activity against SARS-CoV-2 in human cells.

16 Sep 2021

Drug accumulation alters gut bacterial metabolism and composition

In a research paper recently published in the journal Nature by Klünemann et al. (September 8th, 2021), the interaction of 15 diverse drugs with 25 common strains of gut bacteria is investigated, revealing 70 bacteria-drug interactions that include 29 entirely novel mechanisms not yet reported.

15 Sep 2021

HORIBA UK launches new generation Microsemi CRP near-patient haematology analyser

Northampton, UK, 14th September 2021 – HORIBA UK Limited has launched its new generation Microsemi CRP point-of-care haematology analyser.

From HORIBA Scientific UK 14 Sep 2021

Digital spatial profiling of individual glomeruli from HIV and COVID-19 patients

Now, a new study posted to the bioRxiv* server by scientists from the University of Washington explores the use of NanoString’s GeoMx digital spatial profiling (DSP) to investigate CG caused by HIV and SARS-Cov-2 infections.

14 Sep 2021

SARS-CoV-2 may have consequences to host cells beyond evoking an immune response

A recent study examined the ability of SARS-CoV-2 to impact DNA damage response and telomere stability in Vero E6 cells.

13 Sep 2021

Stimulus program increased low-income population’s spending, study reveals

The coronavirus pandemic disrupted the U.S. economy, yet the dynamics of micro-level consumer spending among low-income populations are not well understood.

9 Sep 2021

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

A new study successfully identifies a series of inhibitors that possesses pancoronavirus activity against SARS-CoV, SARS-CoV-2, and MERS-CoV.

7 Sep 2021

Study sheds light on neurologic symptoms caused by SARS-CoV-2 infection

Researchers in Australia and Finland have provided important insights into how infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – might affect nervous system circuitries and cause neurologic symptoms.

6 Sep 2021

UVA research quantifies the antibody response generated by Pfizer and Moderna COVID vaccines

New research from the University of Virginia School of Medicine quantifies the antibody response generated by the Pfizer and Moderna COVID vaccines.

3 Sep 2021

Long-term exposure to low levels of air pollution may be linked to higher mortality

Long-term exposure to air pollution appears to still be linked to higher mortality despite the existence of air quality standards that restrict levels of pollution, suggests a study published online in The BMJ today.

2 Sep 2021

Immune cells present in tumors from head and neck cancer patients, study reports

A new study from scientists at Emory Vaccine Center and Winship Cancer Institute of Emory University reports that the immune cells that are the major targets of immune checkpoint inhibitors are present in tumors from head and neck cancer patients.

2 Sep 2021

New beetle-inspired smart device developed for personalized skin care

Drawing inspiration from nature, a team of international scientists have invented a smart device for personalized skin care modeled after the male diving beetle.

31 Aug 2021

CoronaVac elicits lower antibody response than natural SARS-CoV-2 infection, study suggests

A recent study from Thailand highlights a rather low degree of neutralization-afforded protection mounted by the inactivated whole-virus CoronaVac vaccine compared to natural infection with SARS-CoV-2 – the virus that causes COVID-19.

30 Aug 2021

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

30 Aug 2021

micro News and Research

Is the Pfizer-BioNTech COVID vaccine still effective after 6 months?

New cell-free antibody generation platform successfully creates neutralizing antibodies effective against SARS-CoV-2

Changes in fibrin clot structure contributes to thrombosis risk in severe COVID-19

A novel FACS-based approach for SARS-CoV-2 serology

Large scale 'proteogenomics' study could offer hope to patients with deadly pancreatic cancer

Hypertension in COVID-19-affected pregnancy linked to high SARS-CoV-2 load in placenta

Antiviral compound RG10 acts via intracellular SARS-CoV-2-ER dynamics

Drug accumulation alters gut bacterial metabolism and composition

HORIBA UK launches new generation Microsemi CRP near-patient haematology analyser

Digital spatial profiling of individual glomeruli from HIV and COVID-19 patients

SARS-CoV-2 may have consequences to host cells beyond evoking an immune response

Stimulus program increased low-income population’s spending, study reveals

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

Study sheds light on neurologic symptoms caused by SARS-CoV-2 infection

UVA research quantifies the antibody response generated by Pfizer and Moderna COVID vaccines

Long-term exposure to low levels of air pollution may be linked to higher mortality

Immune cells present in tumors from head and neck cancer patients, study reports

New beetle-inspired smart device developed for personalized skin care

CoronaVac elicits lower antibody response than natural SARS-CoV-2 infection, study suggests

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News